 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1995 | Volume 123 Issue 12 | Pages 897-903
Objective: To evaluate ribavirin, an oral antiviral agent, as therapy for chronic hepatitis C.
Design: Randomized, double-blind, placebo-controlled study.
Setting: Clinical Center of the National Institutes of Health, a tertiary referral research hospital.
Patients: 29 patients with chronic hepatitis C who received oral ribavirin (600 mg twice daily) for 12 months and 29 controls with chronic hepatitis C who received placebo for 12 months.
Measurements: Effects of therapy were evaluated by measuring serum aminotransferase and hepatitis C virus (HCV) RNA levels before, during, and for 6 months after therapy and by histologic examination of liver specimens before and at the end of treatment.
Results: Patients treated with ribavirin had a prompt decrease in serum aminotransferase levels (54% overall) compared with levels before treatment and levels in controls (5% decrease). Serum aminotransferase levels became normal or nearly normal in 10 patients treated with ribavirin (35% [95% CI, 18% to 54%]) but in no controls (0% [CI, 0% to 12%]). Aminotransferase levels remained normal in only 2 patients after ribavirin therapy was discontinued (7% [CI, 1% to 23%]). Serum HCV RNA levels did not change during or after therapy. Liver biopsy specimens showed a decrease in hepatic inflammation and necrosis among ribavirin-treated patients whose aminotransferase levels became normal.
Conclusions: Ribavirin has beneficial effects on serum aminotransferase levels and histologic findings in the liver in patients with chronic hepatitis C, but these effects are not accompanied by changes in HCV RNA levels and are not sustained when ribavirin therapy is discontinued. Thus, ribavirin alone for periods as long as 12 months is unlikely to be of value as therapy for chronic hepatitis C.
Author and Article Information
From the Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
ARTICLE
Ribavirin as Therapy for Chronic Hepatitis C
A Randomized, Double-Blind, Placebo-Controlled Trial
*David Wright, PhD, was also an author on this paper.
Acknowledgments: The authors thank Drs. Humberto Fernandez and Gordana Kosutic from ICN Pharmaceuticals for their advice and assistance and the nursing staff of the Clinical Center, National Institutes of Health, for invaluable patient care.
Grant Support: In part by ICN Pharmaceuticals, who provided the ribavirin capsules, placebo capsules, serologic testing reagents, and fellowship support for Dr. Mahaney; and by Innogenetics, who provided reagents for the genotyping of hepatitis C virus RNA.
Requests for Reprints: Jay H. Hoofnagle, MD, Building 31, Room 9A 23, National Institutes of Health, Bethesda, MD 20892.
Current Author Addresses: Dr. Di Bisceglie: Department of Internal Medicine, St. Louis University Health Sciences Center, 1402 South Grand Boulevard, St. Louis, MO 63104.
Dr. Conjeevaram: Liver Study Unit, Section of Gastroenterology, M454C, University Hospital and Clinics, 5841 South Maryland Avenue, Chicago, IL 60627.
Dr. Fried: Division of Digestive Diseases, Emory University School of Medicine, P.O. Drawer AL, Atlanta, GA 30322.
Drs. Sallie and Park: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Liver Diseases Section, Center Drive, Building 10, 9C306, Bethesda, MD 20892.
Dr. Yurdaydin: Ankara Universitesi, Tip Fakultesi, Cebeci Hastanesi, Cebeci, Ankara, Turkey.
Dr. Swain: Department of Medicine, Faculty of Medicine, Health Sciences Centre, 3330 Hospital Drive N.W., Calgary, Alberta, T2N 1N4, Canada.
Dr. Kleiner: Division of Cancer Biology, Diagnosis and Centers, National Cancer Institute, Center Drive, Building 10, Room 2N206, Bethesda, MD 20892.
Dr. Mahaney: Department of Medicine, Georgetown University Hospital, 3800 Reservoir Road, N.W., Washington, DC 20007.
Dr. Hoofnagle: Building 31, Room 9A 23, National Institutes of Health, Bethesda, MD 20892.
Dr. Wright: Westat, 1650 Research Boulevard, Rockville, MD 20850.
This article has been cited by other articles:
|
|
 |
|
  M. J. Donlin, N. A. Cannon, E. Yao, J. Li, A. Wahed, M. W. Taylor, S. H. Belle, A. M. Di Bisceglie, R. Aurora, J. E. Tavis, et al. Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy J. Virol., August 1, 2007; 81(15): 8211 - 8224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Terrault and D. B. Adey The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 563 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Gish Treating HCV with ribavirin analogues and ribavirin-like molecules J. Antimicrob. Chemother., January 1, 2006; 57(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kato, T. Date, M. Miyamoto, M. Sugiyama, Y. Tanaka, E. Orito, T. Ohno, K. Sugihara, I. Hasegawa, K. Fujiwara, et al. Detection of Anti-Hepatitis C Virus Effects of Interferon and Ribavirin by a Sensitive Replicon System J. Clin. Microbiol., November 1, 2005; 43(11): 5679 - 5684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Matthews and E. J. Bini Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C Journal of Pharmacy Practice, August 1, 2004; 17(4): 229 - 238. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Malek-Ahmadi and E. Ghandour Bupropion for Treatment of Interferon-Induced Depression Ann. Pharmacother., July 1, 2004; 38(7): 1202 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. Buckwold Implications of finding synergic in vitro drug-drug interactions between interferon-{alpha} and ribavirin for the treatment of hepatitis C virus J. Antimicrob. Chemother., March 1, 2004; 53(3): 413 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Buckwold, J. Wei, M. Wenzel-Mathers, and J. Russell Synergistic In Vitro Interactions between Alpha Interferon and Ribavirin against Bovine Viral Diarrhea Virus and Yellow Fever Virus as Surrogate Models of Hepatitis C Virus Replication Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2293 - 2298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zylberberg, B. Nalpas, F. Carnot, H. Skhiri, H. Fontaine, C. Legendre, H. Kreis, C. Brechot, and S. Pol Severe evolution of chronic hepatitis C in renal transplantation: a case control study Nephrol. Dial. Transplant., January 1, 2002; 17(1): 129 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J C L Booth, J O'Grady, and J Neuberger Clinical guidelines on the management of hepatitis C Gut, July 1, 2001; 49(0): I1 - 21. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Tam, K. Ramasamy, J. Bard, B. Pai, C. Lim, and D. R. Averett The Ribavirin Analog ICN 17261 Demonstrates Reduced Toxicity and Antiviral Effects with Retention of both Immunomodulatory Activity and Reduction of Hepatitis-Induced Serum Alanine Aminotransferase Levels Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1276 - 1283. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med, February 15, 2000; 132(4): 296 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Strasser and G. B. McDonald Hepatitis Viruses and Hematopoietic Cell Transplantation: A Guide to Patient and Donor Management Blood, February 15, 1999; 93(4): 1127 - 1136. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. McHutchison, S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M.-H. Ling, S. Cort, J. K. Albrecht, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C N. Engl. J. Med., November 19, 1998; 339(21): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Ning, D. Brown, J. Parodo, M. Cattral, R. Gorczynski, E. Cole, L. Fung, J. W. Ding, M. F. Liu, O. Rotstein, et al. Ribavirin Inhibits Viral-Induced Macrophage Production of TNF, IL-1, the Procoagulant fgl2 Prothrombinase and Preserves Th1 Cytokine Production But Inhibits Th2 Cytokine Response J. Immunol., April 1, 1998; 160(7): 3487 - 3493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Hoofnagle and A. M. Di Bisceglie The Treatment of Chronic Viral Hepatitis N. Engl. J. Med., January 30, 1997; 336(5): 347 - 356. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Chinitz Ribavirin for Chronic Hepatitis C Ann Intern Med, October 15, 1996; 125(8): 699 - 699. [Full Text]
|
|
|
|
|
|
J. H. Hoofnagle and D. Lau Chronic Viral Hepatitis -- Benefits of Current Therapies N. Engl. J. Med., May 30, 1996; 334(22): 1470 - 1471. [Full Text]
|
|
|
|
 |
|
 RIBAVIRIN FOR CHRONIC HEPATITIS C Journal Watch (General), December 26, 1995; 1995(1226): 3 - 3. [Full Text]
|
|
Article
